Drug Trial Radar · NCT06348303
Study to Assess Drowsiness, Cognition, Fall Risk After Metaxalone 640 mg and Metaxalone 800 mg
Last checked: Nov 20, 2026Latest source record: Aug 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
May 16, 2024
Primary completion
Sep 5, 2024
Study completion Oct 30, 2024
Sponsor
- Lead sponsor
- Primus PharmaceuticalsIndustry
- Sponsor type
- Industry
- Collaborators
- ClinOhio Research Services, LLC
- First posted
- Apr 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Crossover
- Masking
- Single (participant)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Every participant will receive Metaxalone in two (2) stages, one week after the other. A single dose of each Metaxalone dose will be taken one (1) time after a high fat meal which must be eaten within 30 minutes. Every participant will be given written tests to measure drowsiness, reaction time and thinking process and will also be asked to take walking tests to assess fall risk. Participation in this study will last approximately 2-4 weeks.
Conditions
- Healthy Participants
Interventions
Metaxalone m640 mg oral tabletDrug
Metaxalone partially micronized 640 mg tablet
Metaxalone 800 mg oral tabletDrug
Metaxalone non-micronized 800 mg oral tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants unable to maintain Tandem Stand Position for more than 10 seconds (position 3 of the 4-Stage Balance Test).Time frame: Baseline, Visit 2 dosing (Day 1), Visit 3 dosing (Day 8)
- Change from baseline of gait during a stopwatch timed, stand, and walk activity from a seated position along a 30 foot pathTime frame: Baseline, Visit 2 dosing (Day 1), Visit 3 dosing (Day 8)
- Change from baseline of correct number of steps taken on a fixed 4 inch wide, 9 feet long pathTime frame: Baseline, Visit 2 dosing (Day 1), Visit 3 dosing (Day 8)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ClinOhio Research Institute
Columbus, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.